^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
i
Other names: MUC1 peptide-polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose adjuvant vaccine, MUC1 - Poly ICLC, Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine, MUC1 peptide-Hiltonol adjuvant vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Pittsburgh
Drug class:
MUC1 inhibitor
Related drugs:
2ms
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov)
P2, N=110, Active, not recruiting, National Cancer Institute (NCI)
Trial completion date • Metastases
|
MUC1 expression
|
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
5ms
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov)
P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
IL6 (Interleukin 6) • MUC1 (Mucin 1) • CRP (C-reactive protein)
|
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
12ms
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov)
P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Dec 2023
Trial completion date
|
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
almost3years
[VIRTUAL] THE REVERSAL OF IMMUNE EXCLUSION MEDIATED BY TADALAFIL AND AN ANTI-TUMOR VACCINE ALSO INDUCES PDL1 UP REGULATION IN RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA: FINAL ANALYSIS INCLUDING CLINICAL OUTCOMES OF A PHASE I CLINICAL TRIAL (AHNS 2021)
The combined treatment of Tadalafil and MUC1/polyICLC vaccine was well tolerated with no serious adverse events or treatment limiting toxicities. All patients were previously irradiated as per study protocol, with 5 of 7 on the active treatment arm and 5 of 6 on the control arm receiving chemotherapy with radiation therapy as part of their prior treatment. Long term (two years) clinical outcomes and toxicity data of 7 evaluable treatment patients and 6 control patients will be reported in addition to long term analyses of the immunomodulatory effects of the treatment intervention.
Clinical • Clinical data • P1 data
|
CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • CD163 (CD163 Molecule)
|
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
Share via
